Veradigm (MDRX) announced that its board of directors completed its previously announced review of strategic alternatives. “Throughout the ...

Veradigm® (OTCMKTS: MDRX), a leading provider of healthcare data and technology solutions, announced today that the Veradigm Board of Directors (the “ ...

23andMe said it's started exploring strategic alternatives, including a possible sale. The company released third-quarter ...

For its internal medicines initiatives, the business has started looking for strategic substitutes including possible asset sales or licencing deals. Unless a clear agreement is achieved or legal ...

The analysis of strategic alternatives will include an assessment of various possible scenarios, including but not limited to raising additional capital or attracting a strategic investor ...

The Special Committee of the board of 23andMe Holding Co. announced that it has undertaken a process to explore strategic alternatives, including, among other alternatives, a poss ...

CEO Anne Wojcicki last spring proposed buying out the company and taking it private. Genetic testing pioneer 23andMe is looking at strategic alternatives, including a possible sale, it said ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

23andMe said it's started exploring strategic alternatives, including a possible sale. The company released third-quarter results that showed an 8% drop in consumer services revenue year over year.